MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in response to ICB is commonly due to a tumor immune escape mechanism dict...

Full description

Bibliographic Details
Main Authors: Ricardo A. de Azevedo, Einav Shoshan, Shanzhi Whang, Gal Markel, Ashvin R. Jaiswal, Arthur Liu, Michael A. Curran, Luiz R. Travassos, Menashe Bar-Eli
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
melanoma
macrophage migratory inhibition factor
tumor microenvironment
immune checkpoint therapy
combined modality therapy
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1846915

Internet

http://dx.doi.org/10.1080/2162402X.2020.1846915

Similar Items